Next 10 |
home / stock / onct / onct articles
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on t...
Although U.S. stocks closed mostly lower on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their conf...
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
As of Jan. 22, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in th...
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition prop...
Shares of Ascent Industries Co. (NASDAQ: ACNT) rose sharply in pre-market trading as the company reported the sale of the business of Specialty Pi...
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.34% to 37,5...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer ...